2021: a key year for allogeneic cellular cancer immunotherapy?

Published: 10 March 2021
Commentary
Sven Kili

Perhaps the key trend in 2020 for the cellular immunotherapy field was the emergence and advancement into the clinic of a new wave of novel allogeneic product candidates.

Allogeneic approaches offer clear advantages over autologous cell therapies, ranging from a less complex, more ‘pharma-friendly’ supply chain and less variable, healthier manufacturing starting materials, through to reduced wait manufacturing bringing Cost of Goods efficiencies, and potentially lower price points for a healthcare sector under growing financial constraints. However, there are some imposing obstacles to be addressed relating to demonstrating both safety and efficacy in the clinic, as well as overcoming scalability issues. In this month’s Clinical Trends, we dissect the development plans and ongoing clinical studies of some of the key industry players.

Read now